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ABSTRACT 
β-lactams are the most widely used group of antimicrobials. However, increasing resistance to 
these valuable drugs in uropathogens, mediated principally by β-lactamases, has become a 
major concern. The present study was undertaken to determine the prevalence of Extended 
Spectrum β-Lactamase (ESBL) producers in clinical isolates of urine specimens, collected 
from various healthcare centres across south Mumbai. A total of 195 gram negative urine iso-
lates were identified as Pseudomonas aeruginosa (13), Proteus mirabilis (21), Klebsiella 
pneumoniae (29), Escherichia coli (96), Enterobacter aerogenes (1), Enterobacter cloacae 
(1), Enterococcus fecalis (1), Morganella morganii (1), Citrobacter diversus (16), Citrobacter 
amalonaticus (5) and Proteus vulgaris (11). Antimicrobial Susceptibility Testing (AST) by 
Kirby-Bauer method showed 43.07 % (84/195) of the isolates were resistant to more than 
70 % of the antibiotics used. Confirmatory screening using a combination of Double Disk 
Synergy Test (DDST), Phenotypic Confirmatory Disc Diffusion Test (PCDDT) and E-test 
revealed the overall prevalence of ESBL producers to be 34.71 % (68/195). The study showed 
72.05 % of the ESBL producers to be resistant to fluoroquinolones, highlighting its extensive 
use in the region of south Mumbai. All ESBL producers were found to be sensitive to 
Imipenem whereas 82.36 % showed susceptibility to Amikacin making these 2 antibiotics the 
most effective choice of drug against ESBLs. In order to ensure rational treatment of highly 
resistant pathogens, the occurrence of ESBL and its primary studies may serve as a base for 
further research and findings. 
 





With over 150 million annual diagnoses 
of Urinary Tract Infections (UTIs) world-
wide, it remains one of the most common 
community-acquired as well as nosocomial 
infections (Gonzalez and Schaeffer, 1999). 
The latter are frequently complicated by 
structural or functional alterations in the 
urinary tract, impaired renal function or 
diseases which impair the immunity, in 
contrast to community-acquired UTIs 
(Mazzuli, 2002; Truls and Bjerklund, 
2006), which are often free of any sort of 
complications. What adds to the problem is 
the emergence of drug resistance among 
uropathogens in the form of Extended 
Spectrum β-Lactamase (ESBL) production. 
ESBLs are chromosomal or plasmid-
mediated β-lactamases (enzymes that 
cleave the β-lactam ring) which have mu-
tated from pre-existing broad-spectrum β-
lactamases (TEM-1, TEM-2, SHV-1) as a 
consequence of widespread use of 3rd gen-
eration Cephalosporins as well as Aztre-
onam (Shukla et al., 2004; Giriyapur et al., 
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2011). ESBLs may be inhibited by β-
lactamase inhibitors such as Clavulanic acid 
or Sulbactam (Bradford, 2001). However, 
several inhibitor-resistant ESBL producers 
are also encountered, by virtue of Amp-C 
lactamase hyper production or loss of porin 
(Ananthan and Subha, 2005). 
ESBLs were first identified in the 1980s 
and have gradually spread throughout the 
world by nosocomial routes. Hospitals 
(Bradford, 2001; Kassis-Chikhani et al., 
2004) and nursing homes (Arpin et al., 
2003; Wiener et al., 1999) have been identi-
fied as important reservoirs of ESBL-
producing Enterobacteriaceae. Patients 
admitted to hospitals are more likely to 
serve as reservoirs for these resistant organ-
isms and eventually, the patients in the 
community acquire ESBL-producing strains 
(Arpin et al., 2003). 
The study of drug resistance in UTI 
causing pathogens is gaining more im-
portance because the resistance mechanism 
of ESBL producers differs from one species 
to another. Moreover the vast number of 
species included in the family Enterobacte-
riaceae further adds to the diagnostic and 
clinical complications associated with 
UTIs. ESBL-producing genes are normally 
harboured on plasmids 80 kb in size or 
larger, and most often carry resistance de-
terminants for aminoglycosides, fluoro-
quinolones, tetracyclines, Chloramphenicol 
and even Cotrimoxizole, making the micro-
organisms resist a wide variety of drugs 
(Chaudhary and Aggarwal, 2004). 
The effectiveness of an antibiotic ad-
ministered to a patient depends on the site 
and severity of the infection, liver and renal 
function, presence of implants and local 
(geographic) resistance patterns. It is also 
believed that the age, pregnancy and lacta-
tion in the patient determine the effective-
ness of the antibiotic used (Chaudhary and 
Aggarwal, 2004). Amoxycillin (β-lactam 
antibiotic) was traditionally used in the first 
line therapy for UTIs, but with the spread of 
drug resistance, other treatment options 
now include Amoxycillin-Clavulanate and 
Cephalosporins like Cefixime, Cefotaxime, 
and Ceftazidime. Fluoroquinolones, though 
used in the treatment of UTIs, are not re-
garded as an acceptable form of antibiotic 
prophylaxis given their cost-ineffectiveness 
and the risk of emergence of organisms re-
sistant to this class of antimicrobials 
(Cendron, 2008). 
Since β-lactam antibiotics are still wide-
ly used, emergence of β-lactamase produc-
ers has become a matter of serious concern. 
The various mechanisms of drug resistance 
in gram-negative bacilli include production 
of β-lactamases (Jarlier et al., 1988), Amp 
C lactamases (Phillippon et al., 2002), ef-
flux mechanisms (Fukuda and Hiramatsu, 
1997) and porin deficiency (Ananthan and 
Subha, 2005). ESBL producers may exhibit 
more than one such resistance mechanism, 
further complicating the situation. 
This study attempts to investigate the 
prevalence of ESBL production among 
gram negative uropathogens and its antibio-
gram pattern using isolates from urine sam-
ples collected from various hospitals and 
pathological laboratories across south 
Mumbai. 
 
MATERIAL AND METHODS 
Collection of samples from south Mumbai 
A total of 225 isolates from urine sam-
ples were collected from 3 government Ter-
tiary care hospitals, 2 private hospitals and 
4 pathological laboratories situated in south 
Mumbai over a period of 6 months (Sep-
tember 2011 to February 2012). These iso-
lates were maintained on Luria-Bertani 
(LB) Agar slants and stored at refrigerated 
conditions. 
 
Isolation and identification 
The cultures were isolated on CLED 
(Cystiene Lactose Electrolyte Deficient) 
Agar and MacConkey’s (MAC) Agar to 
study their cultural characteristics. A single 
isolated colony was considered for further 
studies and identification was done using 
standard conventional, morphological, cul-
tural and biochemical tests (Collee et al., 
1996). 
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Determination of antimicrobial suscepti-
bility to generate an antibiogram pattern 
of the identified pathogens 
Antimicrobial Susceptibility Testing 
(AST) was performed using disk diffusion 
method as described by the Clinical and 
Laboratory Standard Institute (CLSI) using 
Kirby-Bauer method (CLSI, 2012). Dodeca 
discs (PBL-Bio-Disc- code # 612, PBL-
Bio-Disc- code # 212, Pathoteq biological 
laboratories) were used for performing 
AST.  
PBL Biodisc 612 contained Ticarcillin 
(85 mcg), Oxytetracycline (30 mcg), Ceftri-
axone (30 mcg), Cefipime (30 mcg), Ce-
furoxime (30 mcg), Nalidixic acid 
(30 mcg), Norfloxacin (10 mcg), Amoxycil-
lin (30 mcg), Cefadroxil (30 mcg), 
Cefoperazone (75 mcg), Ceftazidime 
(30 mcg), Polymixin-B (300 mcg) and PBL 
Biodisc 212 contained Ampicillin (20 mcg), 
Co-trimoxazole (25 mcg), Cefotaxime 
(30 mcg), Piperacillin (100 mcg), Chloram-
phenicol (30 mcg), Ciprofloxacin (5 mcg), 
Ceftizoxime (30 mcg), Tetracycline 
(30 mcg), Ofloxacin (5 mcg), Gentamicin 
(10 mcg), Amikacin (30 mcg), Gatifloxacin 
(10 mcg).  
E. coli ATCC 25922 was used as a 
standard quality control strain. 
 
ESBL screening 
All the isolates showing resistance to 3rd 
generation cephalosporins, namely Ceftaz-
dime, Ceftriaxone and Cefotaxime, were 
further tested for confirmation of β-
lactamase production by phenotypic meth-
ods. The Optical Density (O.D.) of the cul-
tures were adjusted to 0.1 (at 530 nm) and 
swabbed on Mueller-Hinton (MH) Agar 
plates for further studies. The screening was 
done as per CLSI guidelines (CLSI, 2012) 
mentioned in Table 1. 
Table1: Standard zone sizes of antibiotics for 
ESBL screening as per CLSI guidelines (CLSI, 
2012) 
Antibiotics Strength Zone size 
Aztreonam 
30 mcg 
< 27 mm 
Ceftriaxone < 26 mm 
Cefotaxime < 22 mm 
Ceftazidime < 27 mm 
 
Phenotypic confirmatory disk diffusion 
test (PCDDT) for ESBL detection 
Ceftazidime (30 mcg) was used alone as 
well as in combination with Clavulanic acid 
(10 mcg). Both the disks were placed on 
MH Agar plates pre-swabbed with the re-
spective culture and incubated at 37 °C for 
24 h. An increase in the zone diameter for 
Ceftazidime-Clavulanic acid by ≥ 5mm was 
considered positive for ESBL production 
(CLSI, 2010). 
 
Double disk synergy test (DDST) 
DDST was carried out using 5 antibiot-
ics, namely Amoxycillin-Clavulanic acid 
(20/10 mcg), Aztreonam (30 mcg), Cefo-
taxime (30 mcg), Ceftriaxone (30 mcg) and 
Ceftazidime (30 mcg). The disks were 
placed at a distance of 1.5 cm from a cen-
trally-placed Amoxycillin-Clavulanic acid 
disk. Enhancement of the zone of inhibition 
towards the Clavulanate disk after 24 hrs 
incubation at 37 °C was considered indica-
tive of a potential ESBL producer (Jarlier et 
al., 1988). 
 
Confirmation of ESBL production by  
E-test 
Confirmation of ESBL production was 
done using Multi-Ezy MICTM Strips (Hi-
Media Laboratories Pvt. Ltd.). These strips 
differ from the conventional E-strips in that 
they contain a gradient of 3 antibiotics with 
and without Clavulanic acid on either sides 
of the strip respectively instead of one anti-
biotic. The Multi-Ezy MICTM Strips used 
contained Cefotaxime, Ceftazidime and 
Cefipime (MIX) on one side in a two-fold 
gradient and the same antibiotics with 
Clavulanic acid (MIX+) on the other side. 
A ratio of inhibition zones for MIX and 
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MIX+ of ≥ 8 was considered as a positive 
E-test (CLSI, 2011). Reference cultures 
used in the study were E. coli ATCC 25922 
as negative control and Klebsiella pneu-
moniae ATCC 700603 as positive control. 
 
RESULTS 
In the present study, 225 isolates were 
collected from various healthcare centres, 
out of which 195 isolates were character-
ised as gram negative. These isolates were 
identified using conventional cultural, bio-
chemical and morphological tests, and 
comprised of Pseudomonas aeruginosa 
(13), Proteus mirabilis (21), Klebsiella 
pneumoniae (29), Escherichia coli (96), 
Enterobacter aerogenes (1), Enterobacter 
cloacae (1), Enterococcus fecalis (1), Mor-
ganella morganii (1), Citrobacter diversus 
(16), Citrobacter amalonaticus (5) and Pro-
teus vulgaris (11).  
Antibiotic sensitivity test was carried 
out using Kirby Bauer method (Figure 1). 
Around 88.20 % (172/195) isolates were 
found to be resistant to more than 3 antibi-
otics. Among these cultures, 43.07 % 
(84/195) isolates were resistant to over 
70 % antibiotics used in the study including 
3rd generation Cephalosporins (Ceftazi-
dime, Cefotaxime and Ceftriaxone). 
Figure 1: Antibiotic sensitivity test (AST) show-
ing highly resistant strain of Citrobacter diver-
sus (resistant to 20 of the 24 tested antibiotics) 
 
These cultures were further checked for 
ESBL production by PCDDT, DDST and 
E-test (Figure 2). Clavulanic acid was used 
as a β-lactamase inhibitor in the above tests. 
Confirmatory tests for detection of ESBL 
producers using Ezy-MICTM strips showed 
34.87 % (68/195) of the isolates to be 











Figure 2: Isolate 70 (E. coli.) showing: (a) Posi-
tive PCDDT when swabbed on MH Agar and 
incubated with Ceftazidime (left) and Cefta-
zidime-Clavulanate (right). (b) Positive DDST 
when swabbed on MH Agar and incubated with 
(clockwise from top-left) Ceftazidime, Ceftriax-
one, Cefotaxime, Aztreonam, and Amoxycillin-
Clavulanate at the centre. (c) E-test showing 
positive ESBL production, with a ratio of Antibi-
otic: Antibiotic-Clavulanic acid > 8 
 
Table 2: ESBL producing uropathogens 
Pathogens No of  isolates 
ESBL  
Producers




Proteus mirabilis 21 4 




















Total 195 68 
a b 
c 
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The antibiogram pattern for the isolates 
analysed showed ESBL-producing isolates 
to possess a higher degree of resistance to-
wards antibiotics that are routinely pre-
scribed against urinary tract infections as 
compared to non-ESBL-producing isolates 
(Figure 3). ESBL producers showed around 
90 % resistance to antibiotics like Ceftazi-
dime, Ceftriaxone, Cefotaxime, Naladixic 
acid and Ampicillin (Figure 3). Resistance 
to Ciprofloxacin was exhibited by 72.05 % 
(48/68) of the ESBL producers. 
Resistance to Amikacin was found to be 
comparatively lower in both ESBL and 
non-ESBL producers. Gentamicin, Chlor-
amphenicol and Ampicillin were found to 
be more effective on non-ESBLs as com-




In India, the prevalence of ESBLs has 
been reported since the 1990s (Revathi and 
Singh, 1997; Karim et al., 2001; Mathai et 
al., 2002; Gupta et al., 2007; Aggarwal et 
al., 2009; Narayanaswamy and Mallika, 
2011) with very few reports from south In-
dia published (Padmini and Raju, 2004; 
Menon et al., 2006; Jemima and Verghese, 
2008; Mano and Vasanthi, 2008; Kamatchi 
et al., 2009; Narayanaswamy and Mallika, 
2011; Gururajan et al., 2011). 
 
 
Figure 3: Antibiogram showing resistance pattern of ESBL and non-ESBL-producing uropathogens 
towards different antibiotics 
 
EXCLI Journal 2012;11:363-372 – ISSN 1611-2156 
Received: June 09, 2012, accepted: July 02, 2012, published: July 06, 2012 
 
368 
The phenotypic data generated in the 
current study indicates a high prevalence 
of ESBL producers in the region of south 
Mumbai (situated in the western part of 
India), where 68 out of 195 (34.87 %) uro-
pathogens were found to be ESBL produc-
ers. With a hot and humid climate preva-
lent in Mumbai, incidences of UTIs are 
constantly on the rise. Statistics have 
shown that ESBL-producing E. coli are 
found to be the highest in India (60 %), 
followed by Hong Kong (48 %) and Sin-
gapore (33 %) (Hsueh et al., 2011).  
In the current study, 96 of the 195 iso-
lates (49.23 %) were identified as E. coli, 
of which 36 isolates (49.32 %) were ESBL 
producers. General studies have revealed 
E. coli to be one of the most frequently en-
countered drug-resistant uropathogens 
(Gupta et al., 1999, 2007; Tambekar et al., 
2006); a fact clearly reflected in the current 
study carried out in south Mumbai. The 
study however showed only 8 out of 29 
(27.5 %) Klebsiella pneumoniae isolates to 
be ESBL producers, which is generally the 
second most common uropathogen and a 
frequent ESBL producer (Gales et al., 
2002; Mathur et al., 2002). Overall, 
88.20 % (172/195) isolates were found to 
be resistant towards multiple drugs.  
A recent study in Chennai reported 
ESBL production among 47 % E. coli and 
37 % Klebsiella pneumoniae in a tertiary 
care centre (Gururajan et al., 2011). An-
other study conducted in the suburbs of 
Chennai showed ESBL production among 
75.5 % E. coli isolates (Maya et al., 2011). 
Frequency of ESBL production in Islama-
bad and Rawalpindi was found to be 48 
and 35 % respectively among E. coli iso-
lates (Zaman et al., 1999). 
Other countries, in comparison with 
India, show a reduced incidence of ESBL 
producers. A study has shown that the 
prevalence of ESBL producing isolates of 
E. coli is 13.3 % in Lebanon, 9.2 % in Ko-
rea, 10.3 % in Arabia and 17 % in Turkey 
(Ananthan and Subha, 2005). However 
there is a constant increase in the popula-
tion of ESBL producing strains in commu-
nities of other countries (Arpin et al., 2003; 
Borer et al., 2002; Wiener et al., 1999; Pat-
erson et al., 2003). 
Mumbai has witnessed a gradual rise in 
the number of antibiotic-resistant microor-
ganisms, primarily stemming from admin-
istering drugs without any preceding isola-
tion or sensitivity tests which is coupled 
with poverty and illiteracy among the 
masses. This has given way to improper 
dosing, lack of completion of the pre-
scribed course and the use of leftover drugs 
(Akram et al., 2007). In concurrence, this 
study reflects a comparatively high per-
centage of ESBL producers (34.87 %) in 
the region under study. 
The antibiogram pattern (Figure 3) of 
uropathogens shows a higher degree of re-
sistance in ESBL producers as compared to 
non-ESBL producers. It also revealed that 
49 of 68 (72.05 %) ESBL producers were 
resistant to Ciprofloxacin, one of the most 
commonly used fluoroquinolone drugs 
which might be indicative of fluoroquin-
olones being prescribed at a high frequen-
cy in south Mumbai. Although fluoroquin-
olones should not be prescribed routinely 
for UTIs (Burka et al., 2005; Park-Wyllie 
et al., 2006; Coleman et al., 2002), such a 
high degree of resistance clearly shows the 
misuse of antibiotics by healthcare profes-
sionals. Several of the commonly-used 
fluoroquinolones have been known to ex-
hibit a host of side effects and are, for this 
reason, banned in India (Adams and 
Tavakoli, 2006).  
Gatifloxacin, a fluoroquinolone, was 
banned in India on the 18th of March 2011, 
with a statement issued by the health min-
istry stating “the use of the following drugs 
is likely to involve certain risks to human 
beings, whereas safer alternatives to the 
said drugs are available”. This move comes 
after international studies revealed Gati-
floxacin to pose a 17 times higher risk of 
developing serious hyperglycaemia (high 
blood sugar) in comparison to other anti-
biotics in elderly patients (Adams and 
Tavakoli, 2006). 
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An individual is at a significantly high-
er risk of being infected by ESBL-produc-
ing uropathogens if he/she is exposed to 
antibiotics for a long period of time, is kept 
in the ICU for a long time period, suffers 
from any severe illness, undergoes instru-
mentation or catheterization procedures or 
is a resident in nursing homes or institutes 
which frequently use 3rd generation cepha-
losporins (Chaudhary and Aggarwal, 
2004). Under such circumstances, fluoro-
quinolones become the drug of choice. 
However, Ciprofloxacin also shows many 
side effects if given in slightly higher doses 
and hence its extensive use should be 
avoided. It is hence advised that it should 
be used only in cases where the bacterial 
load is extremely high (Cendron, 2008). 
Since the data in the current study is not 
confined to any specific healthcare centre, 
it is evident that fluoroquinolones are ex-
tensively used throughout south Mumbai. 
A low degree of resistance to Amikacin 
(an aminoglycoside drug) was observed for 
both ESBL and non-ESBL producers and 
hence may be helpful in combating severe 
infections. ESBL producers showed re-
sistance to β-lactam antibiotics as well as 
non-β-lactam antibiotics. All ESBL pro-
ducers were sensitive to carbapenems 
which are used as last resort drugs. These 
results are in accordance with the findings 
in a tertiary care hospital based in south 
India (Padmini et al., 2008). 
The current study, which examines the 
spread of drug resistance among uropatho-
gens in south Mumbai, is, to our aware-
ness, the first of its kind as it is not restrict-
ed to a specific healthcare centre. Addi-
tional studies can be carried out with a 
larger sample size to obtain a more conclu-
sive scenario and possibly extend its impli-
cations to other regions of Mumbai city. 
The results obtained can be confirmed us-
ing molecular studies to check whether the 
widespread resistance is due to a specific 
gene or multiple genes.  
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